Tokyo, Japan, June 16th, 2015 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that REGPARA® Tablets 12.5mg (generic name: cinacalcet hydrochloride) has been launched today, June 16th, 2015 in Japan.
REGPARA® acts on calcium receptors on the parathyroid gland to suppress the secretion of parathyroid hormone (PTH). REGPARA® tablets 25mg and 75mg were launched in January 2008 for secondary hyperparathyroidism (HPT) in patients who are undergoing regular dialysis. In February 2014, REGPARA® had received the approval for hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy or who experience recurrent primary HPT.
REGPARA® Tablets 12.5mg was listed on the National Health Insurance Drug Price List on May 29th, 2015 after the approval in Japan on February 10th, 2015. REGPARA® has been marketed in Japan for seven years and prescribed to many patients, but individual patients vary in their response to or tolerance of the drug. REGPARA®Tablets 12.5mg, a lower dosage form, is expected to allow doctors to more finely adjust the drug dose.
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
